ETA Receptor Blockade Prevents Increased Tissue Endothelin-1, Vascular Hypertrophy, and Endothelial Dysfunction in Salt-Sensitive Hypertension

Hypertension

Volumn 31, Issue 1, 1998, Pages 499-504

  Barton, Matthias ^a   d'Uscio, Livius V ^a   Shaw, Sidney ^a   Meyer, Peter ^a   Moreau, Pierre ^a   Luscher, Thomas F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; NITRIC OXIDE; SODIUM CHLORIDE; ACETYLCHOLINE; DARUSENTAN; ENDOTHELIN RECEPTOR; NITROPRUSSIDE SODIUM; PHENYLPROPIONIC ACID DERIVATIVE; POTASSIUM CHLORIDE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; ENDOTHELIUM INJURY; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SODIUM INTAKE; VASCULAR ENDOTHELIUM; ANIMAL; BIOSYNTHESIS; BLOOD PRESSURE; DRUG ANTAGONISM; DRUG EFFECT; HYPERTROPHY; IN VITRO STUDY; METABOLISM; MUSCLE CONTRACTION; PATHOLOGY; PATHOPHYSIOLOGY; RAT STRAIN; SYSTOLE; THORACIC AORTA; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ACETYLCHOLINE; ANIMALS; AORTA, THORACIC; BLOOD PRESSURE; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HYPERTENSION; HYPERTROPHY; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; NITROPRUSSIDE; PHENYLPROPIONATES; POTASSIUM CHLORIDE; PYRIMIDINES; RATS; RATS, INBRED STRAINS; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; SODIUM, DIETARY; SYSTOLE; VASODILATION;

EID: 0031613530     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.HYP.31.1.499     Document Type: Article

References (45)

1. Gotto AM, Farmer JA. Risk factors for coronary artery disease. In: Braunwald, ed. Heart Disease, 2nd ed. Philadelphia: W.B. Saunders; 1992:1125-1160.
2. Pecker MS. Salt sensitivity in hypertensive patients: pathogenesis, identification, and treatment. In: Laragh JH, Brenner, BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management, 2nd ed. New York: Raven Press; 1995:2543-2555.
3. Kaplan N. Systemic hypertension: mechanisms and diagnosis. In: Braunwald, ed. Heart Disease, 2nd ed. Philadelphia: W.B. Saunders; 1992:817-851.
4. Kawasaki T, Delea CS, Bartter FC, Smith H. The effect of high-sodium and low-sodium intakes on blood pressure and other related variables in human subjects with idiopathic hypertension. Am J Med. 1978;64:193-198.
5. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension. 1996;27:481-490.
6. Lariviere R, Day R, Schiffrin EL. Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Hypertension. 1993;21:916-920.
7. Dahl LK, Heine M, Tassinari L. Role of generic factors in susceptibility to experimental hypertension due to chronic excess salt ingestion. Nature. 1962;194:480-482.
8. Rapp JP. Dahl salt-susceptible and salt-resistant rats. Hypertension. 1982;4:753-763.
9. Luscher TF, Raij L, Vanhoutte PM. Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats. Hypertension. 1987;9:157-163.
10. Limas C, Westrum B, Iwai J, Limas CJ. Aortic morphology in salt-dependent genetic hypertension. Am J Pathol. 1982;107:378-394.
11. Luscher TF, Vanhoutte PM. The Endothelium: Modulator of Cardiovascular Function. Boca Raton, Fla.: CRC Press; 1990:1-215.
12. Goligorsky MS, Iijima K, Morgan M, Yanagisawa M, Masaki T, Lin L, Nasjletti A, Kaskel F, Frazer M, Badr KF. Role of endothelin in the development of Dahl hypertension. J Cardiovasc Pharmacol. 1991;17(Suppl 7):S484-S491.
13. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
14. Dubin D, Pratt RE, Cooke JP, Dzau VJ. Endothelin, a potent vasoconstrictor, is a vascular smooth muscle mitogen. J Vasc Med Biol. 1989;1:13-17.
15. Alberts GF, Paifley KA, Johns A, Kleha Jf, Winkles JA. Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop. J Biol Chem. 1994;269:10112-10118.
16. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990;348:730-732.
17. Ohlstein EH, Arleth A, Elliott JD, Sung CP. The selective endothelin-A receptor antagonist BQ-123 antagonizes ET-1 mediated mitogenesis in vascular smooth muscle. Eur J Pharmacol. 1992;225:347-350.
18. d'Uscio LV, Moreau P, Shaw S, Takase H, Barton M, Luscher TF. Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension. Hypertension. 1997;29:435-441.
19. Moreau P, d'Uscio LV, Takase H, Shaw S, Barton M, Luscher TF. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: Reversal by ETA-antagonist. Circulation. 1997;96:1593-1597.
20. Kung CF, Luscher TF. Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension. 1995;25:194-200.
21. Hayakawa H, Raij L. The link among nitric oxide synthase activity, endothelial function, and aortic and ventricular hypertrophy in hypertension. Hypertension. 1997;29:235-241.
22. Sventek P, Li JS, Grove K, Deschepper CF, Schiffrin EL. Vascular structure and expression of endothelin-1 gene in L-NAME-treated spontaneously hypertensive rats. Hypertension. 1996;27:49-55.
23. Chen L, McNeill JR, Wilson TW, Gopalakrishan V. Heterogeneity in vascular smooth muscle responsiveness to angiotensin II: role of endothelin. Hypertension. 1995;26:83-88.
24. Barton M, Cosentino F, Brandes RP, Moreau P, Shaw S, Luscher TF. Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin. Hypertension. 1997;30:817-824.
25. Owen MP, Walmsley JG, Mason MF, Bevan RD, Bevan JA. Adrenergic control in three artery segments of diminishing diameter in rabbit ear. Am J Physiol. 1983;245:H320-H326.
26. Hisaki K, Matsumura Y, Maekawa H, Fujita K, Takaoka M, Morimoto S. Conversion of big ET-1 in the rat lung: role of phosphoramidon-sensitive endothelin-1-converting enzyme. Am J Physiol. 1996;266:H422-H428.
27. Luscher TF, Vanhoutte PM, Raij L Antihypertensive treatment normalizes decreased endothelium-dependent relaxations in rats with salt-induced hypertension. Hypertension. 1987;9(Suppl III):193-197.
28. Riechers H, Albrecht HP, Amberg W, Baumann E, Bernard H, Bohm HJ, Klinge D, Kling A, Muller S, Raschack M, Unger L, Walker N, Wernet W. Discovery and optimization of a novel class of orally active nonpeptidic endothelin-A receptor antagonists. J Med Chem. 1996;39:2123-2128.
29. Wallenstein S, Zucker CL, Fleiss J. Some statistical methods useful in circulation research. Circ Res. 1980;47:1-9.
30. Raij L, Luscher TF, Vanhoutte PM. High potassium diet augments endothelium-dependent relaxations in the Dahl rat. Hypertension. 1988;12:562-567.
31. Luscher TF, Noll G. Endothelium-dependent vasomotion in aging, hypertension and heart failure. Circulation. 1993;87(Suppl VII):VII97-VII103.
32. Lariviere R, Thibault G, Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension. 1993;21:294-300.
33. Li J-S, Schiffrin EL. Effect of chronic treatment of adult spontaneously hypertensive rats with an endothelin receptor antagonist. Hypertension. 1995;25:495-500.
34. Barton M, Shaw S, d'Uscio LV, Moreau P, Luscher TF. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun. 1997;238:861-865.
35. Wagner OF, Christ G, Wojta J, Vierhapper H, Parzer S, Nowotny PJ, Schneider B, Waldhausl W, Binder BR. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem. 1992;267:16066-16068.
36. Hahn AW, Resink TJ, Scott-Burden T, Powell J, Dohi Y, Buhler FR. Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function. Cell Regul. 1990;1:649-659.
37. Fujisaki H, Ito H, Hirata Y, Tanaka M, Hata W, Lin M, Adachi S, Akimoto H, Marumo F, Hiroe M. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest. 1995;96:1059-1065.
38. Boulanger C, Luscher TF. Release of endothelin from the porcine aorta: inhibition by endothelium-derived nitric oxide. J Clin Invest. 1990;85:587-590.
39. Filep JG. Endogenous endothelin modulates blood pressure, plasma volume, and albumin escape after systemic nitric oxide blockade. Hypertension. 1997;30:22-28.
40. Ikeda U, Yamamoto K, Maeda Y, Shimpo M, Kanbe T, Shimada K. Endothelin-1 inhibits nitric oxide synthesis in vascular smooth muscle cells. Hypertension. 1997;29:65-69.
41. Hirata Y, Emori T, Eguchi S, Kanno K, Imai T, Ohta K, Marumo F. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest. 1993:91:1367-1373.
42. Boulanger CM, Desta B, Clozel JP, Vanhoutte PM. Chronic treatment with the Ca2 + channel inhibitor RO 40-5967 potentiates endothelium-dependent relaxations in the aorta of the hypertensive salt sensitive Dahl rat. Blood Press. 1994;3:193-196.
43. d'Uscio LV, Shaw S, Barton M, Luscher TF. Impaired endothelial function and increased tissue endothelin in angiotensin II-induced hypertension: effects of treatments with losartan and verapamil (abstract). Hypertension. 1997;30:510.
44. Hocher B, Thone-Reinecke C, Rohmeiss P, Schmager F, Slowinski R, Burst V, Siegmund F, Quertermous T, Bauer C, Neumayer HH, Schleuning WD, Theuring F. Endothelin-1 transgenic mice develop glomerulosclerosis, intersitial fibrosis, and renal cysts but not hypertension. J Clin Invest. 1997;99:1380-1389.
45. Kurihara H, Kurihara Y, Maemura K, Yazaki Y. The role of endothelin-1 in cardiovascular development. Ann NY Acad Sci. 1997;811:168-177.